This initiative will provide the necessary investments to
advance first-in-class drug - apabetalone for the potential
treatment of COVID-19 within the Arab-African Economy
CALGARY, Alberta, Canada - November 3, 2021 -
InvestorsHub NewsWire - Resverlogix Corp. ("Resverlogix" or the
Company") (TSX: RVX), a world leader in epigenetics or gene
regulation, is pleased to announce today that it has entered into a
cooperation agreement with the Supreme Council of the Arab-African
Economy which has expressed an interest in providing necessary
investments and partnerships to support the entry of Resverlogix's
first-in-class drug - apabetalone into the Arab-African
Economy.
"We are excited to be collaborating with the Supreme Council of
the Arab-African Economy under the leadership of His Excellency Dr.
Hani Abu Zaid," said Donald J. McCaffrey, President & CEO of
Resverlogix. "By entering into this cooperation agreement, it will
assist our approach in strengthening our relationships,
developments, and interests within the Arab-African Economy, while
propelling the development of apabetalone," further commented Mr.
McCaffrey.
"The Supreme Council of the Arab-African Economy is pleased to
be in collaboration with Resverlogix to provide the necessary
investment and assistance to support the emergence of apabetalone
into the Arab-African Economy. We look forward to working with Mr.
McCaffrey and his team of world-class scientists and experts in the
field of epigenetics," stated His Excellency Dr. Hani Abu Zaid,
President of the Supreme Council for the Arab-African Economy.
Resverlogix has been actively working with hospitals and the
respective ministries globally to
commence COVID-19 clinical trials. On October 12th, 2021
Resverlogix received ethics committee approval for
Western Canadian sites in a Phase 2 clinical trial for apabetalone
in COVID-19 patients. On November 1st, 2021 the Canadian
arm of the trial began actively recruiting patients. Additionally,
a Phase 3 COVID-19 trial in the US is anticipated to commence in
coming months based on final protocol approval.
Phase 2 Trial Overview - Canada/Brazil
Study participants will be made up of patients hospitalized with
confirmed COVID-19 cases. Participants will either receive twice
daily doses of apabetalone for up to 4 weeks alongside standard of
care, compared to standard of care alone. The primary outcome
measure of the study will be change in the World Health
Organization (WHO) Ordinal Scale for Clinical Improvement. A total
of 100 patients are expected to be enrolled at multiple sites in
Canada and Brazil. The study is actively recruiting in the Canadian
arm. The full study protocol can be found on
clinicaltrials.gov.
About the Supreme Council of Arab-African Economy
- The Council's Mandate
The Supreme Economic Council for the Arab-African Economy is an
economic-diplomatic body recognized by the United Nations, European
Union, Arab League, and the Common Market for Eastern and Southern
Africa (COMESA). The Supreme Economic Council for the Arab-African
Economy specializes in promoting and facilitating investments and
trade in member nations and affiliates to strengthen their
economies.
About Apabetalone
Apabetalone (RVX-208), is a first-in-class, epigenetic small
molecule, or gene regulating, therapeutic candidate. It is a
selective BET (bromodomain and
extra-terminal) inhibitor, which
works in preventing disease by turning genes on and/or off through
regulation of gene expression. The prevalence of BET proteins in
the human body allows apabetalone, through its unique mechanism of
action, to simultaneously target multiple disease-causing
biological processes while maintaining a well described safety
profile - leading to a new way to treat chronic disease.
Cardiology:
In February 2020, apabetalone became the first therapy of its
kind to receive Breakthrough Therapy Designation by the US Food and
Drug Administration (FDA) - for a major cardiovascular indication -
following the ground-breaking findings from the BETonMACE Phase
Three study. Data from BETonMACE showed apabetalone can potentially
prevent major adverse cardiac events among high-risk cardiovascular
disease patients who also have type 2 diabetes mellitus.
Covid-19:
On March 23, 2020,
Resverlogix launched its COVID-19 program, enlisting world-renowned
collaborators. Studies demonstrate that apabetalone has the
potential to act against COVID-19 with a unique dual-mechanism: the
first pillar of apabetalone's dual-mechanism is preventing viruses
from entering the cells and replicating; the second pillar is
averting runaway inflammatory reactions that can cause severe and
lasting organ damage. A Phase 2
clinical trial is evaluating apabetalone in combination with
standard of care for patients hospitalized with COVID-19.
Apabetalone treatment could potentially reduce the severity and
duration of COVID-19. Apabetalone's unique dual-mechanism also
means that it is likely to show efficacy against COVID-19 variants
and may even help fight other related viruses.
Apabetalone is the only drug of its class with a
well-established safety record in human clinical trials, with well
over 4200 patient-years on drug across 10 clinical trials.
About Resverlogix
Founded in 2001, Resverlogix is a Calgary based late-stage
biotechnology company and the world leader in epigenetics, or gene
regulation, with the goal of developing first-in-class therapies
for the benefit of patients with chronic disease.
Resverlogix is commercializing a new class of epigenetic
therapies designed to regulate gene expression, turning
disease-associated genes "on" or "off". We aim to improve patients'
lives by restoring biological functions - altered by serious
illnesses such as cardiovascular disease - back to a healthier
state.
The Company's clinical program is focused on evaluating the lead
epigenetic candidate apabetalone for the treatment of
cardiovascular disease and associated comorbidities, and
COVID-19.
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
Follow us: Twitter: @Resverlogix_RVX.
LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
www.resverlogix.com
Forward Looking Statements:
This news release may contain certain forward-looking
information as defined under applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
In particular, this news release includes forward looking
information related to the Company's discussions with the
Supreme Council of Arab-African Economy, the
Company's clinical trials and the potential role of apabetalone
in the treatment of patients with COVID-19 (and potentially other
viruses), cardiovascular disease and associated comorbidities and
other chronic diseases. Our actual results, events or developments
could be materially different from those expressed or implied by
these forward-looking statements. We can give no assurance that any
of the events or expectations will occur or be realized. By their
nature, forward-looking statements are subject to numerous
assumptions and risk factors including those discussed in our
Annual Information Form and most recent MD&A which are
incorporated herein by reference and are available through SEDAR at
www.sedar.com. The forward-looking statements contained in this
news release are expressly qualified by this cautionary statement
and are made as of the date hereof. The Company disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Resverlogix (TSX:RVX)
Historical Stock Chart
From Oct 2024 to Nov 2024
Resverlogix (TSX:RVX)
Historical Stock Chart
From Nov 2023 to Nov 2024
